152 related articles for article (PubMed ID: 16900637)
61. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
[TBL] [Abstract][Full Text] [Related]
62. Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature.
Ogando-Rivas E; Alalade AF; Boatey J; Schwartz TH
Pituitary; 2017 Dec; 20(6):702-708. PubMed ID: 28766078
[TBL] [Abstract][Full Text] [Related]
63. Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.
Heaney AP
Pituitary; 2003; 6(3):153-9. PubMed ID: 14971739
[TBL] [Abstract][Full Text] [Related]
64. Immunohistochemical demonstration of insulin-like growth factor I (IGF-1) in normal and pathological human pituitary glands.
Alberti VN; Takita LC; de Mesquita MI; Percário S; Maciel RM
Pathol Res Pract; 1991 Jun; 187(5):541-2. PubMed ID: 1717961
[TBL] [Abstract][Full Text] [Related]
65. HDAC2 expression and variable number of repeats in exon 1 of the HDAC2 gene in corticotroph adenomas.
Evang JA; Borota OC; Melum E; Holm R; Ramm-Pettersen J; Bollerslev J; Berg JP
Clin Endocrinol (Oxf); 2010 Aug; 73(2):229-35. PubMed ID: 20346000
[TBL] [Abstract][Full Text] [Related]
66. Vascular networks and endothelial cells in the rat experimental pituitary glands and in the human pituitary adenomas.
Itoh J; Serizawa A; Kawai K; Ishii Y; Teramoto A; Osamura RY
Microsc Res Tech; 2003 Feb; 60(2):231-5. PubMed ID: 12539177
[TBL] [Abstract][Full Text] [Related]
67. Expression and clinical relevance of paired box protein 7 and sex determining region Y-box 2 in canine corticotroph pituitary adenomas.
van Rijn SJ; Pouwer MG; Tryfonidou MA; Grinwis GC; van der Bend JE; Beukers PE; Vastenhout N; Drouin J; Penning LC; Meij BP
Vet J; 2015 Jun; 204(3):315-21. PubMed ID: 25956343
[TBL] [Abstract][Full Text] [Related]
68. Gene expression in pituitary adenomas: new insights.
McNicol AM
Microsc Res Tech; 1997 Oct; 39(2):182-93. PubMed ID: 9361269
[No Abstract] [Full Text] [Related]
69. Decreased expression of survivin 2B in human pituitary adenomas. A preliminary study.
Waligorska-Stachura J; Sawicka-Gutaj N; Zabel M; Liebert W; Gut P; Czarnywojtek A; Ruchala M
Folia Histochem Cytobiol; 2017; 55(1):21-25. PubMed ID: 28509313
[TBL] [Abstract][Full Text] [Related]
70. Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas.
Mezzomo LC; Gonzales PH; Pesce FG; Kretzmann Filho N; Ferreira NP; Oliveira MC; Kohek MB
Pituitary; 2012 Sep; 15(3):420-7. PubMed ID: 21850407
[TBL] [Abstract][Full Text] [Related]
71. [The expression and significance of CD151 in pituitary adenomas].
Li S; Hong Y; Hu ZC; Jin X; Sun PP; Nie LW; Zhou YF
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2015 Mar; 31(2):182-5. PubMed ID: 26248430
[TBL] [Abstract][Full Text] [Related]
72. SOX 2 Expression in Human Pituitary Adenomas-Correlations With Pituitary Function.
Capatina C; Cimpean AM; Raica M; Coculescu M; Poiana C
In Vivo; 2019; 33(1):79-83. PubMed ID: 30587606
[TBL] [Abstract][Full Text] [Related]
73. Expression pattern of neuronal intermediate filament α-internexin in anterior pituitary gland and related tumors.
Schult D; Hölsken A; Buchfelder M; Schlaffer SM; Siegel S; Kreitschmann-Andermahr I; Fahlbusch R; Buslei R
Pituitary; 2015 Aug; 18(4):465-73. PubMed ID: 25236435
[TBL] [Abstract][Full Text] [Related]
74. [EXPRESSION AND SIGNIFICANCE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR γ IN KELOID].
Lei L; Deng Y; Chen J; Cen Y
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2016 Sep; 30(9):1143-1145. PubMed ID: 29786372
[TBL] [Abstract][Full Text] [Related]
75. Expression of the pituitary stem/progenitor marker GFRα2 in human pituitary adenomas and normal pituitary.
Mathioudakis N; Sundaresh R; Larsen A; Ruff W; Schiller J; Guerrero-Cázares H; Burger P; Salvatori R; Quiñones-Hinojosa A
Pituitary; 2015 Feb; 18(1):31-41. PubMed ID: 24402129
[TBL] [Abstract][Full Text] [Related]
76. Targeting pituitary tumors.
Heaney AP
Horm Res; 2007; 68 Suppl 5():132-6. PubMed ID: 18174730
[TBL] [Abstract][Full Text] [Related]
77. [Treatment of pituitary adenomas: recent topics].
Izumoto S; Arita N
No Shinkei Geka; 2010 Jan; 38(1):79-89. PubMed ID: 20085107
[No Abstract] [Full Text] [Related]
78. Ubiquitin-specific Protease 8 Gene Expression in Sporadic Pituitary Adenomas.
Hatipoglu E; Gunaldi O; Erkan B; Avcikurt A; Mert M; Niyazoglu M
Neuro Endocrinol Lett; 2022 Jun; 43(2):129-133. PubMed ID: 35981231
[TBL] [Abstract][Full Text] [Related]
79. A novel approach to anticancer therapies: peroxisome proliferator activator-receptor-gamma as a new target therapy in the treatment of human urological cancer.
Matsuyama M; Yoshimura R
Endocr Metab Immune Disord Drug Targets; 2009 Mar; 9(1):76-83. PubMed ID: 19275683
[TBL] [Abstract][Full Text] [Related]
80. Leptin and peroxisome proliferator-activated receptor γ expression in colorectal adenoma.
Kim HH; Kim YS; Kang YK; Moon JS
World J Gastroenterol; 2012 Feb; 18(6):557-62. PubMed ID: 22363123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
